DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. In a filing with the SEC, ...
Activist investor Elliott Investment Management has taken a stake in medical device firm Dexcom Inc. and struck a settlement ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
DexCom reported a sales miss in the second quarter. (Courtesy DexCom) Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance, and grim news ...
DexCom is a major player in the continuous glucose monitoring (CGM) market. These devices help diabetes patients monitor their blood sugar levels in real time throughout the day, an activity that is ...
When companies post strong earnings, the stock generally performs well, just like DexCom, Inc.'s ( NASDAQ:DXCM ) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results